These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24400769)

  • 1. The multitarget drug approach in migraine treatment: the new challenge to conquer.
    González-Hernández A; Condés-Lara M
    Headache; 2014 Jan; 54(1):197-9. PubMed ID: 24400769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging target-based paradigms to prevent and treat migraine.
    Silberstein SD
    Clin Pharmacol Ther; 2013 Jan; 93(1):78-85. PubMed ID: 23212108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache.
    Olesen J
    Pharmacol Ther; 2008 Nov; 120(2):157-71. PubMed ID: 18789357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging treatment for chronic migraine and refractory chronic migraine.
    Lionetto L; Negro A; Palmisani S; Gentile G; Del Fiore MR; Mercieri M; Simmaco M; Smith T; Al-Kaisy A; Arcioni R; Martelletti P
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):393-406. PubMed ID: 22862686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future pharmacologic targets for acute and preventive treatments of migraine.
    Buchanan TM; Ramadan NM; Aurora S
    Expert Rev Neurother; 2004 May; 4(3):391-430. PubMed ID: 15853537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we develop neurally acting drugs for the treatment of migraine?
    Goadsby PJ
    Nat Rev Drug Discov; 2005 Sep; 4(9):741-50. PubMed ID: 16121129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models.
    Bhatt DK; Gupta S; Jansen-Olesen I; Andrews JS; Olesen J
    Cephalalgia; 2013 Jan; 33(2):87-100. PubMed ID: 23155193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
    Blumenfeld A; Gennings C; Cady R
    Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding new drug targets for the treatment of migraine attacks.
    Olesen J; Tfelt-Hansen P; Ashina M
    Cephalalgia; 2009 Sep; 29(9):909-20. PubMed ID: 19250288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan.
    Goadsby PJ; Hargreaves RJ
    Neurology; 2000; 55(9 Suppl 2):S8-14. PubMed ID: 11089513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine: current concepts and emerging therapies.
    Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
    Vascul Pharmacol; 2005 Sep; 43(3):176-87. PubMed ID: 16099727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of needle-free sumatriptan injection for rapid control of migraine.
    Rothrock JF; Freitag FG; Farr SJ; Smith EF
    Headache; 2013 Sep; 53 Suppl 2():21-33. PubMed ID: 24024600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of endothelial and neuronal nitric oxide synthase in dura and pia mater after air stress.
    Zinck T; Illum R; Jansen-Olesen I
    Cephalalgia; 2006 Jan; 26(1):14-25. PubMed ID: 16396662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of novel glutamate receptor antagonists in migraine.
    Andreou AP; Goadsby PJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):789-803. PubMed ID: 19426123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
    Géraud G; Valette C
    Rev Neurol (Paris); 2000 Jul; 156(6-7):646-53. PubMed ID: 10891800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging migraine treatments and drug targets.
    Olesen J; Ashina M
    Trends Pharmacol Sci; 2011 Jun; 32(6):352-9. PubMed ID: 21459461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining the interrelationship of migraine onset, duration, and time to treatment.
    Landy SH; Runken MC; Bell CF; Higbie RL; Haskins LS
    Headache; 2012 Mar; 52(3):363-73. PubMed ID: 22077159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
    Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
    Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sumatriptan iontophoretic transdermal system: history, study results, and use in clinical practice.
    Pierce M; O'Neill C; Felker E; Sebree T
    Headache; 2013 Sep; 53 Suppl 2():34-42. PubMed ID: 24024601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New triptan preparations can help the migraine patient. Pharmacodynamic and pharmacokinetic progresses].
    Dahlöf CG
    Lakartidningen; 1998 Nov; 95(46):5175, 5178-82, 5184-6. PubMed ID: 9842191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.